AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop ...

The story with AbbVie (NYSE: ABBV) in 2024 is that it fell off a patent cliff but survived. It survived and continues to ...

AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current ...

AbbVie (ABBV) and EvolveImmune Therapeutics announced a collaboration and option-to-license agreement to develop multispecific ...

The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

With growth catalysts in place, along with dividend payouts, AbbVie is a good medium to long-term buy. Click here to read an ...

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO, Ill.

NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics ...